Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives (Q37862648)

24 August 2017

1 reference

title

Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives (English)

1 reference

24 August 2017

1 reference

lymphoblastic leukemia

1 reference

Hun J Lee

1

1 reference

24 August 2017

James E Thompson

series ordinal

2

1 reference

24 August 2017

Eunice S Wang

series ordinal

3

1 reference

24 August 2017

Meir Wetzler

series ordinal

4

1 reference

24 August 2017

language of work or name

English

0 references

publication date

8 November 2010

1 reference

24 August 2017

1 reference

24 August 2017

117

1 reference

24 August 2017

8

1 reference

24 August 2017

1583-1594

1 reference

Treatment of acute lymphoblastic leukemia

24 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Clinical and prognostic significance of the Philadelphia chromosome in adult patients with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Philadelphia-chromosome-positive adult acute lymphocytic leukemia: characteristics, treatment results, and prognosis in 41 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Allogeneic haematopoietic stem cell transplant in Philadelphia-positive acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Active transport of imatinib into and out of cells: implications for drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

With a little help from small friends: Enhanced chemotherapeutic effects with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Philadelphia chromosome positive acute lymphocytic leukemia: a new era of challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Re: Imatinib mesylate administration in the first 100 days after stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Danusertib (formerly PHA-739358)--a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

7 January 2021

Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche de

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

7 January 2021

Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

7 January 2021

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

7 January 2021

Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

7 January 2021

Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

7 January 2021

Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25690

7 January 2021

Identifiers

DOI

10.1002/CNCR.25690

1 reference

24 August 2017

1 reference